Search results for: Disintegrin
#34127028 2021/06/14 To Up
Expression of VEGF-A Signaling Pathway in Cartilage of ACLT-induced Osteoarthritis Mouse Model.Anterior cruciate ligament transection surgery (ACLT)-induced OA model was often used to investigate the molecular mechanism of knee osteoarthritis (KOA). Researches have shown that vascular endothelial growth factor (VEGF) played an important role in OA. The present study aimed to investigate the pathological changes after ACLT surgery and reveal the expression characteristics of the VEGF-A/VEGFR2 signaling pathway in this model.
Jia-Jia Qian, Qi Xu, Wei-Min Xu, Ren Cai, Gui-Cheng Huang
2254 related Products with: Expression of VEGF-A Signaling Pathway in Cartilage of ACLT-induced Osteoarthritis Mouse Model.2 Pieces/Box2 Pieces/Box100 ul2 Pieces/Box2 Pieces/Box2 Pieces/Box50 ul2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box
#34125393 2021/06/14 To Up
The miR-302c/transforming growth factor-Î² receptor type-2 axis modulates interleukin-1Î²-induced degenerative changes in osteoarthritic chondrocytes.Chondrocyte production of catabolic and inflammatory mediators participating in extracellular matrix degradation has been regarded as a central event in osteoarthritis (OA) development. During OA pathogenesis, interleukin-1Î² (IL-1Î²) decreases the mRNA expression and protein levels of transforming growth factor-Î² receptor type-2 (TGFBR2), thus disrupting transforming growth factor-Î² signaling and promoting OA development. In the present study, we attempted to identify the differentially expressed genes in OA chondrocytes upon IL-1Î² treatment, investigate their specific roles in OA development, and reveal the underlying mechanism. As shown by online data analysis and experimental results, TGFBR2 expression was significantly downregulated in IL-1Î²-treated human primary OA chondrocytes. IL-1Î² treatment induced degenerative changes in OA chondrocytes, as manifested by increased matrix metalloproteinase 13 and a disintegrin and metalloproteinase with thrombospondin motifs 5 proteins, decreased Aggrecan and Collagen II proteins, and suppressed OA chondrocyte proliferation. These degenerative changes were significantly reversed by TGFBR2 overexpression. miR-302c expression was markedly induced by IL-1Î² treatment in OA chondrocytes. miR-302c suppressed the expression of TGFBR2 via direct binding to its 3'- untranslated region. Similar to TGFBR2 overexpression, miR-302c inhibition significantly improved IL-1Î²-induced degenerative changes in OA chondrocytes. Conversely, TGFBR2 silencing enhanced IL-1Î²-induced degenerative changes and significantly reversed the effects of miR-302c inhibition in response to IL-1Î² treatment. In conclusion, the miR-302c/TGFBR2 axis could modulate IL-1Î²-induced degenerative changes in OA chondrocytes and might become a novel target for OA treatment.
Yiyue Chen, You Chen, Wanchun Wang, Junhua Chen, Qi Tang, Ren Wu, Weihong Zhu, Ding Li, Lele Liao
1425 related Products with: The miR-302c/transforming growth factor-Î² receptor type-2 axis modulates interleukin-1Î²-induced degenerative changes in osteoarthritic chondrocytes.20ug2 Pieces/Box100 μg100.00 ug96 wells (1 kit)5ug96T250ul4 Membranes/Box96T100.00 ug
#34116684 2021/06/11 To Up
MiR-24-3p attenuates IL-1Î²-induced chondrocyte injury associated with osteoarthritis by targeting BCL2L12.MiR-24-3p has been reported to be involved in an osteoarthritis (OA)-resembling environment. However, the functional role and underlying mechanism of miR-24-3p in chondrocyte injury associated with OA remains unknown.
Jin Xu, Xiaozhong Qian, Ren Ding
1907 related Products with: MiR-24-3p attenuates IL-1Î²-induced chondrocyte injury associated with osteoarthritis by targeting BCL2L12.50 ul50ug1 mg 100ul96 assays5ug2ug100 ul100ug400 ug96T
#34113115 2021/06/03 To Up
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy secondary to a severely decreased A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats 13 (ADAMTS13) activity, resulting in the formation of widespread von Willebrand factor - and platelet-rich microthrombi. ADAMTS13 deficiency is mainly acquired through anti-ADAMTS13 autoantibodies in adults. With modern standards of care, unresponsive TTP has become rarer with a frequency of refractory/relapsing forms dropping from >40% to <10%. As patients with unresponsive TTP are at increased risk of mortality, prompt recognition and early therapeutic intensification are mandatory. Therapeutic options at the disposal of clinicians caring for patients with refractory TTP consist of increased ADAMTS13 supplementation, increased immunosuppression, and inhibition of von Willebrand factor adhesion to platelets. In this work, we focus on possible therapies for the management of patients with unresponsive TTP, and propose an algorithm for the management of these difficult cases.
Virginie Lemiale, Sandrine Valade, Eric Mariotte
2894 related Products with: Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.25 mg2.5 mg10 mg100ug500 MG25 mg50 ug 96T100ul50 mg10 mg1000 tests
#34109776 2021/06/10 To Up
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.Shedding of A Disintegrin And Metalloproteinases (ADAM10) substrates, like TNFÎ± or CD30, can affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. We have published two new ADAM10 inhibitors, LT4 and MN8 able to prevent such shedding in Hodgkin lymphoma (HL). Since tumor tissue architecture deeply influence the outcome of anti-cancer treatments, we set up new three-dimensional (3D) culture systemsto verify whether ADAM10 inhibitors can contribute to, or enhance, the anti-lymphoma effects of the ADC brentuximab-vedotin (BtxVed).To recapitulate some aspects of lymphoma structure and architecture, we assembled two 3D culture models: mixed spheroids made of HL lymph node (LN) mesenchymal stromal cells (MSC) and Reed Sternberg/Hodgkin lymphoma cells (HL cells) or collagen scaffolds repopulated with LN-MSC and HL cells. In these 3D systems we found that: 1) the ADAM10 inhibitors LT4 and MN8 reduce ATP content or glucose consumption, related to cell proliferation, increasing lactate dehydrogenase (LDH) release as a cell damage hallmark; 2) these events are paralleled by mixed spheroids size reduction and inhibition of CD30 and TNFÎ± shedding; 3) the effects observed can be reproduced in repopulated HL LN-derived matrix or collagen scaffolds; 4) ADAM10 inhibitors enhance the antilymphoma effect of the anti-CD30 ADC BtxVed both in conventional cultures and in repopulated scaffolds. Thus, we provide evidence for direct and combined anti-lymphoma effect of ADAM10 inhibitors with BtxVed, leading to improvement of ADC effects; this is documented in 3D models recapitulating features of LN microenvironment, that can be proposed as reliable tool for antilymphoma drug testing.
Roberta Pece, Sara Tavella, Delfina Costa, Serena Varesano, Caterina Camodeca, Doretta Cuffaro, Elisa Nuti, Armando Rossello, Massimo Alfano, Cristina D'Arrigo, Denise Galante, Jean-Louis Ravetti, Marco Gobbi, Francesca Tosetti, Alessandro Poggi, Maria Raffaella Zocchi
1920 related Products with: Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.100ul1000 tests100ug Lyophilized100ug100ug100ug Lyophilized100ug100ug100ug Lyophilized100ul1000 tests100ug Lyophilized
Error loading info... Pleas try again later.
#34105490 // To Up
[Biological Function of CysR Domain of ADAMTS13].To investigate the biological function of Cysteine rich (CysR) domain of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 (ADAMTS13) on cleavage of von Willebrand factor (vWF) and provide experimental evidence for exploring the pathogenesis of thrombotic thrombocytopenic purpura (TTP).
Hao Wu, Hua Li, Chang Su, Hong-Yan Li, Ri-Hua Cui, Sheng-Yu Jin 5 G100μg200.00 ug250ul100ul100μg1 kit(96 Wells)0.2 mg100 ug100ug100μg5ml
#34105247 2021/06/08 To Up
Acquired Thrombotic Thrombocytopenic Purpura: a rare disease associated Acquired with BNT162b2 vaccine.In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon have been described after receiving vaccinations. Here we describe a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura, a rare autoimmune disease, within several days of receiving the BNT162b2 vaccine. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13(ADAMTS13) activity should be evaluated in patients with history of aTTP before and after any vaccination, especially the SARS-CoV-2 vaccination, and immunosuppression treatment should be considered before vaccination in cases of low ADAMTS13 activity. Patients should be closely monitored after the vaccine for clinical situation and laboratory data. Post vaccination thrombocytopenia assessment should include immune thrombocytopenic purpura, vaccine-induced immune thrombotic thrombocytopenia and acquired thrombotic thrombocytopenic purpura.
Hannah Maayan, Ilya Kirgner, Odit Gutwein, Katrin Herzog-Tzarfati, Naomi Rahimi-Levene, Maya Koren-Michowitz, Dorit Blickstein
1744 related Products with: Acquired Thrombotic Thrombocytopenic Purpura: a rare disease associated Acquired with BNT162b2 vaccine.500 tests430 Tests / Kit100
#34103247 2021/05/19 To Up
Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.We evaluated the stroma marker A Disintegrin And Metalloprotease 12 (ADAM12) as a preoperative prognostic and treatment-predictive marker for overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) and periampullary cancers.
Marin Strijker, Fleur van der Sijde, Mustafa Suker, Marja A Boermeester, Bert A Bonsing, Marco J Bruno, Olivier R Busch, Michail Doukas, Casper H van Eijck, Arja Gerritsen, Bas Groot Koerkamp, Nadia Haj Mohammad, Jony van Hilst, Ignace H de Hingh, Jeanin E van Hooft, Misha D Luyer, I Quintus Molenaar, Joanne Verheij, Cynthia Waasdorp, Johanna W Wilmink, Marc G Besselink, Hanneke W van Laarhoven, Maarten F Bijlsma,
2372 related Products with: Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.96T
#34089819 2021/06/02 To Up
BIOACTIVITY, BIOAVAILABILITY, AND GUT MICROBIOTA TRANSFORMATIONS OF DIETARY PHENOLIC COMPOUNDS: IMPLICATIONS FOR COVID-19.The outbreak of mysterious pneumonia at the end of 2019 is associated with widespread research interest worldwide. The coronavirus disease-19 (COVID-19) targets multiple organs through inflammatory, immune, and redox mechanisms, and no effective drug for its prophylaxis or treatment has been identified until now. The use of dietary bioactive compounds, such as phenolic compounds (PC), has emerged as a putative nutritional or therapeutic adjunct approach for COVID-19. In the present study, scientific data on the mechanisms underlying the bioactivity of PC and their usefulness in COVID-19 mitigation are reviewed. In addition, antioxidant, antiviral, anti-inflammatory, and immunomodulatory effects of dietary PC are studied. Moreover, the implications of digestion on the putative benefits of dietary PC against COVID-19 are presented by addressing the bioavailability and biotransformation of PC by the gut microbiota. Lastly, safety issues and possible drug interactions of PC and their implications in COVID-19 therapeutics are discussed.
Paula R Augusti, Greicy M M Conterato, Cristiane C Denardin, InÃªs D Prazeres, Ana Teresa Serra, Maria R Bronze, Tatiana Emanuelli
2829 related Products with: BIOACTIVITY, BIOAVAILABILITY, AND GUT MICROBIOTA TRANSFORMATIONS OF DIETARY PHENOLIC COMPOUNDS: IMPLICATIONS FOR COVID-19.100ul100ug10 mg 500 ml 50 mg250 mg0.1 ml25 mg100.00 ul5 mg2.5 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia